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  P
ractitioners of pediatric medicine 
may still be undecided as to 
whether the newer generation 
of antidepressant drugs is effective 
for child and adolescent depression 
(CAD) [1]. Since 1989, when selective 
serotonin reuptake inhibitors (SSRIs) 
were introduced in the United States, 
they have become the top-selling drug 
category; as many as one in eight adult 
Americans having tried at least one 
SSRI in the past ten years. Despite 
their popularity in treating adult 
depression, the efﬁ  cacy of SSRIs for 
CAD remains in dispute. In this article, 
I examine some of the core problems 
in medical research that have led to 
this disagreement.
  Speciﬁ  city, Safety, and Efﬁ  cacy
    Advances in molecular biology 
and neuroscience have fostered 
increasingly speciﬁ  c drugs. However, 
the pharmaceutical industry promotes 
an idea of drug speciﬁ  city that may 
extend beyond the existing data. For 
example, SSRIs may selectively block 
the reuptake of serotonin, as claimed 
by many SSRI manufacturers, but they 
also inﬂ  uence numerous postsynaptic 
serotonin receptor systems, instigating 
multiple neurochemical effects. 
Furthermore, certain neurotransmitter 
systems are so tightly entwined that 
affecting one inevitably inﬂ  uences 
others (e.g., selective norepinepherine 
reuptake inhibitors also inﬂ  uence the 
serotonergic system). Hence, drugs 
often have effects that seem unrelated 
to the presumed therapeutic outcome 
(e.g., tricyclic antidepressants [TCAs] 
and SSRIs have signiﬁ  cant effects on 
fast sodium channels and platelet 
function, respectively). And one 
drug can treat a variety of syndromes. 
For example, SSRIs are effective for 
symptoms ranging from obsessive-
compulsive disorder to panic and 
anxiety. Thus, speciﬁ  city, as deﬁ  ned by 
the pharmaceutical industry, is perhaps 
an overextended notion.
    Antidepressant medications have 
become central to managing CAD [2]. 
Because double-blind trials of TCAs 
have failed to show greater efﬁ  cacy 
than placebo for treating CAD [3,4], 
and concerns have been raised about 
the side effects of TCAs, SSRIs have 
been seen as the viable option for 
treating CAD [5]. Indeed, the 21st 
century ushered in major clinical 
guidelines endorsing SSRIs as ﬁ  rst-
line pharmacotherapy for CAD in 
both North America and the United 
Kingdom [6,7]. Most rigorous studies 
that tested the safety and efﬁ  cacy 
of these medications in depressed 
adolescents began after these drugs 
were deemed “ﬁ  rst line” by the 
professional community of child and 
adolescent psychiatrists.
    Yet the recent history of SSRIs is 
replete with inconsistent verdicts 
about their safety. For example, 
in January 2003, the US Food 
and Drug Administration (FDA) 
approved ﬂ  uoxetine for children 
and adolescents. However, about 
ﬁ  ve months later, concerns arose 
among psychiatrists about whether 
the drug was associated with suicidal 
thinking and behavior in children 
and adolescents. Nevertheless, in 
December 2003, the UK Medicines 
and Healthcare Products Regulatory 
Agency (MHRA) supported the use of 
ﬂ  uoxetine in children and adolescents 
[8,9]. It stated that for three other 
SSRIs (sertraline, citalopram, and 
escitalopram) the risks outweighed 
the beneﬁ  ts, while the balance of 
risks and beneﬁ  ts was “unassessable” 
for a fourth SSRI, ﬂ  uvoxamine [8]. 
In September 2004, based on a 
review of 24 trials of nine different 
antidepressant drugs that were used 
to treat CAD, obsessive compulsive 
disorder, or “other psychiatric 
disorders,” the FDA also supported 
the use of ﬂ  uoxetine in treating CAD 
[10]. Prior to this, on March 22, 2004, 
the FDA had issued a “black box” 
warning label on all antidepressants, 
cautioning that these medications may 
“increase the risk of suicidal thinking 
and behavior (suicidality) in children 
and adolescents with major depressive 
disorder (MDD) and other psychiatric 
disorders” [11].
    In its September 2004 review, 
the FDA endorsed SSRI safety as 
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well as an arbitrary improvement 
criterion—some decrease, relative to 
placebo, on a reputable scale (e.g., 
a two-point drop on the Hamilton 
depression scale)—without addressing 
actual clinical efﬁ  cacy. However, the 
resulting assumption among some 
practitioners was that SSRIs in general 
are effective, as well as safe, for CAD. 
This conclusion is consistent with 
recent reviews [12,13], drawing on 
both published and unpublished data, 
reporting that at least ﬂ  uoxetine is 
seen as a safe and efﬁ  cacious treatment 
for CAD. The tendency to embrace 
SSRIs for CAD demonstrates a trend in 
pediatric mental health practice toward 
taking efﬁ  cacy for granted and focusing 
on safety. 
  Statistical  Signiﬁ  cance versus 
Clinical Signiﬁ  cance
    Paying too much attention to 
signiﬁ  cance tests and too little attention 
to the analysis methods [14] or other 
aspects of the data (e.g., the estimates 
of the magnitude of the effects [15]) 
may blur the difference between 
statistical signiﬁ  cance and clinical 
importance [16,17]. Furthermore, 
statistical signiﬁ  cance itself can be 
clinically meaningless. 
    For example, a hypothetical study 
with a large sample size might show 
that an average heart rate of 69 on 
placebo compared to 71 on a drug is 
statistically signiﬁ  cant, but this effect is 
likely to be clinically meaningless. In 
fact, the only standard for determining 
drug efﬁ  cacy for “quality-of-life 
illnesses,” including CAD, is a placebo-
controlled trial; a comparator (i.e., a 
“horse-race,” or “drug A versus drug 
B”) trial typically boosts the drug effect 
(P. Roose, personal communication 
and [18]). (This is partly due to the 
fact that when people know that they 
are being treated with either a more 
or less potent medicine, drug response 
tends to be more vigorous than when 
they know that they may be on either 
an actual drug or a placebo). Finally, 
scientiﬁ  c experiments rarely control 
for variables known to inﬂ  uence drug 
response (e.g., expectation, suggestion, 
motivation, site location, and trial 
length) (P. Roose, unpublished data). 
    Clinical signiﬁ  cance—a meaningful 
change in the symptomatic state 
or functioning of an individual 
patient—requires independent 
replication of results [19]. Different 
ﬁ  elds have different criteria for 
clinical signiﬁ  cance. Additionally, the 
statistical method used to calculate 
clinical signiﬁ  cance affects the 
estimates of meaningful change [14]. 
Indeed, some professional associations 
(e.g., the American Psychological 
Association) have deemed effect sizes 
and conﬁ  dence intervals to be more 
meaningful measures than signiﬁ  cance 
testing [20].
    To determine clinical signiﬁ  cance 
through “risk-beneﬁ  t” analysis 
[21], one must weigh the potential 
beneﬁ  t of improved symptomatology, 
accompanied by adverse side effects, 
against the risk of leaving the disease 
untreated. Trying to address the issue 
of clinical signiﬁ  cance, researchers 
have considered such parameters as 
the number needed to treat (NNT), 
the number needed to harm, and the 
number needed to prevent [22]. In 
the case of depression and CAD, FDA 
approval of ﬂ  uoxetine implies that the 
FDA considered the number needed 
to harm to be reasonable. But what is a 
good value for NNT? Ideally, it would 
be as close as possible to one (i.e., we 
need to treat only one person in order 
to see a desired effect in one person), 
but actually the NNT tends to be much 
higher than one [23], and it is unclear 
what range of values permits clinicians 
to conclude that a favorable beneﬁ  t-to-
risk ratio exists. 
    In addition, the NNT must be 
interpreted by using a comparison 
group. For example, in a placebo 
controlled trial, NNT = 3 means that on 
average one of three patients will derive 
speciﬁ  c beneﬁ  t from the treatment 
above and beyond placebo, which is 
rarely used clinically. Thus, NNT may 
be more clinically meaningful as an 
active comparator than in relation to a 
placebo. The absence of clear criteria 
for clinical efﬁ  cacy is probably partially 
responsible for interpretation of the 
same data as being both for [24] and 
against [25] the efﬁ  cacy of a speciﬁ  c 
drug.
    Lacking clear criteria for clinical 
signiﬁ  cance, statistical signiﬁ  cance 
is perhaps the most convenient 
substitute [26]. But researchers 
may pay too much attention to the 
results of signiﬁ  cance tests, thereby 
overlooking clinical signiﬁ  cance. 
Statistical signiﬁ  cance may not be a 
sufﬁ  cient criterion for recommending 
a drug [27]. In the case of adult 
antidepressants, FDA approval 
requires that two randomized 
clinical trials (RCTs) show that drug 
performance is at least two Hamilton-
scale points better than a placebo; 
however, this arbitrary criterion does 
not signify clinical efﬁ  cacy. In fact, 
it is unclear what criteria should be 
used to assess clinical signiﬁ  cance. 
For example, how many studies 
are needed to convince a clinician 
that a drug is efﬁ  cacious? Clinical 
signiﬁ  cance relies on replication and 
probably requires a meta-analysis. 
  Table 1.   A List of Published and Unpublished Sources Commonly Cited in Recent 
Reviews Reporting on SSRIs for Child and Adolescent Depression   
Primary Data Source [52] [53] [50] [55]
Published Fluoxetine [38] X X X




(Sertraline)b [95]  XXXX
(Citalopram) [54] Xc X
(Fluoxetine) [23] X







  aNot included meta-analysis by [52].
  b Two separate trials analyzed and published together. 
  cReviewed prior to publication (draft differed slightly from published paper).
    This table is an updated version of Table 1 in [13]. Only the more recent studies account for unpublished data, which are important to the formulation of a 
comprehensive and informed opinion regarding drug efﬁ  cacy and safety.
  DOI:  10.1371/journal.pmed.0030009.t001 
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Recent [21,50] as well as future meta-
analyses, including one currently 
under preparation by A. Drews, I. 
Kirsch, and D.O. Antonuccio entitled 
“A Meta-Analysis of Antidepressants 
Trials for Depressed Children: 
Small Beneﬁ  ts, Large Stakes”, may 
further illuminate the efﬁ  cacy of 
antidepressants for CAD.
  Belief  Systems
    While strong opinions on either side of 
any controversy may appear extreme, 
it is important not to disregard these 
beliefs immediately. For example, 
on February 2, 2004, Irving Kirsch 
and David Antonuccio offered their 
testimony to the FDA on the efﬁ  cacy of 
antidepressants for treating children 
with depression. At that time, only 
a dozen RCTs had examined the 
efﬁ  cacy of antidepressants in CAD 
(four assessed SSRIs, seven assessed 
TCAs, and one assessed both SSRIs and 
TCAs) [28–38] (see sidebar). Eight of 
these RCTs failed to ﬁ  nd any signiﬁ  cant 
beneﬁ  t of medication over placebo. 
While no TCA-placebo comparisons 
showed signiﬁ  cant differences, four of 
the ﬁ  ve SSRI-placebo RCTs (plus a ﬁ  fth 
that included SSRIs and TCAs) claimed 
signiﬁ  cant differences between drug 
and placebo, but only on clinician-
rated, not patient-rated, measures.
    Since either means or standard 
deviations were missing in 25% of 
these RCTs, only nine were amenable 
to meta-analytic scrutiny. When Kirsch 
and Antonuccio combined data from 
these nine studies for analysis, the 
placebo response was 87% of the drug 
response, 75% of the SSRI response, 
and 97% of the TCA response. These 
results seem to indicate that TCAs 
have no signiﬁ  cant pharmacological 
effect on CAD. They concluded that 
the effect of SSRIs may be statistically 
signiﬁ  cant, but possibly not clinically 
signiﬁ  cant.
    While some psychopharmacologists 
dismiss investigators such as Kirsch and 
Antonuccio as “outliers” or inherently 
biased against the drug industry, such 
“outlying” accounts should nevertheless 
be examined. Opinions on either side 
of this issue should be considered, 
especially in the absence of deﬁ  nitive 
data and facts.
  Market  Forces
    In the US, the pharmaceutical 
industry, Congress, and advocacy 
groups are known to both lobby and 
contribute generously to the FDA 
and may partially inspire its decisions 
and policies (P. Roose, personal 
communication). The inﬂ  uence of the 
pharmaceutical industry permeates 
science [39], and evidence points to 
the increasing commercial impact 
of biomedical research on scientiﬁ  c 
reporting [40,41]. Indeed, industry 
funding for research tends to yield 
favorable reports concerning the tested 
drug [42]. For example, among the 
authors of original research papers, 
reviews, and letters to the editor that 
were supportive of the use of speciﬁ  c 
drugs, 96% had ﬁ  nancial relationships 
with the drugs’ manufacturers, whereas 
for publications deemed neutral or 
critical, the ﬁ  gures were only 60% and 
37%, respectively [43,44].
    Further, since negative results are 
often discounted or not published 
[45,46,47], the message conveyed 
to the popular press and the public 
is often positively skewed [48], 
emphasizing beneﬁ  ts over risks and 
predicting improbable breakthroughs 
[49]. This trend may create unrealistic 
expectations about scientiﬁ  c 
advances or products and may lead to 
inappropriate and expensive utilization 
patterns. However, commercial 
pressure is not the only source of 
ambitious interpretations; another is 
researchers who are eager to promote 
their latest ﬁ  ndings. Thus, conﬂ  icts of 
interest in SSRI trials for treating CAD 
may potentially cloud results.
  Different  Reviews  Have 
Had Different Results
    Although most previous reviews have 
been partisan, a few have presented 
a balanced account [1,50,51]. The 
ﬁ  rst, though least comprehensive, 
review of RCTs conducted on newer 
antidepressants for CAD examined six 
published studies, including studies on 
venlafaxine and three SSRIs: ﬂ  uoxetine 
(three studies), sertraline (one study), 
and paroxetine (one study) [52]. In 
their limited meta-analysis, the authors 
used a random effects model to pool 
averaged, selected outcomes across the 
ﬁ  ve SSRI studies. They found a small 
effect size of 0.26 (95% conﬁ  dence 
interval [CI], 0.13–0.40), which they 
described as equivalent to a three-to-
four-point improvement on the revised 
children’s depression rating scale 
(which ranges from 17 to 113). They 
concluded that a large beneﬁ  t from 
newer antidepressant drugs is unlikely. 
Reviewing the same studies, another 
report judged the efﬁ  cacy data to be 
inconclusive [53].
    Since the above reviews [52,53] 
included in their analysis a negative 
study of ﬂ  uoxetine which involved a 
small (n = 30), clinically heterogeneous 
(mixed inpatients and outpatients) 
participant group [39], some later 
reviews opted to exclude this negative 
study from their analyses. For example, 
one study analyzed ﬁ  ve of the six 
published papers addressed in the 
above-mentioned reviews [52,53], 
as well as data from six unpublished 
studies accessed through collaboration 
with the UK’s MHRA [50]. These 
unpublished studies included 
two investigations of venlafaxine, 
paroxetine, and citalopram, respectively 
(one of the citalopram studies was 
subsequently published [54]). After 
extracting raw data for outcome 
measures, including remission, response 
January 2006  |  Volume 3  |  Issue 1  |  e9
  Incentives for Conducting 
Pediatric Clinical Trials
  Giving  pharmaceutical  companies 
an incentive to conduct pediatric tests, 
Congress passed the FDA Modernization 
Act in November 1997. Section 111 of 
this “pediatric exclusivity” partnership 
act offered drug sponsors six months 
(sometimes up to a year) of additional 
market exclusivity if they conducted 
pediatric studies on drugs still under 
some exclusivity provision. Under 
the FDA Modernization Act, the 
pharmaceutical company could continue 
to set the market price, keeping generic 
forms of the drug off the market. The 
original act has since been revised 
and extended through 2007 under 
the Best Pharmaceuticals for Children 
Act, but concerns still linger regarding 
disproportionate proﬁ  ts accrued by drug 
companies from the six-month extension 
compared to the cost of clinical trials, 
and the absence of commitment by the 
companies to publish or make readily 
available the safety and efﬁ  cacy results 
of these trials [92]. While it is easy to see 
why pharmaceutical companies are eager 
to conduct pediatric research (six-month 
worldwide exclusivity for ﬂ  uoxetine, for 
example, is estimated to be worth about 
a billion dollars), clinicians and patients 
rarely have access to these ﬁ  ndings [93]. PLoS Medicine  |  www.plosmedicine.org 0038
to treatment, and depressive symptoms 
scores, the authors reanalyzed, 
and—where possible—meta-analyzed 
published and unpublished studies 
of each drug, using ﬁ  xed-effects and 
random-effects models. The authors 
concluded that only ﬂ  uoxetine had 
evidence of efﬁ  cacy that was robust: 
across two published trials, ﬂ  uoxetine 
was more likely than placebo to bring 
about remission (number needed to 
beneﬁ  t 6; 95% CI, 4–15), or a clinically 
meaningful response (number needed 
to beneﬁ  t 5; 95% CI, 4–13). The study 
did not draw on unpublished ﬂ  uoxetine 
efﬁ  cacy data.
    The most recent systematic review 
of newer antidepressants for CAD 
to date [55] included all of the data 
previously reviewed [50,52,53] as well 
as unpublished data regarding two 
RCTs of nefazodone, and the recently 
published Treatment for Adolescents 
with Depression Study (TADS) [23], 
which compared ﬂ  uoxetine, placebo, 
and cognitive behavioral therapy (CBT) 
alone and in combination (see Table 
1). After examining efﬁ  cacy outcomes 
and the inﬂ  uence of methodology 
(site selection, study population, study 
design, and outcome measures) on 
those outcomes, the authors found that 
the more methodologically sound SSRI 
studies tended to have better outcomes. 
For example, in the TADS, 60.6% 
(95% CI, 51%–70%) of adolescents 
responded to ﬂ  uoxetine alone, as 
opposed to a 34.8 (95% CI, 26%– 44%) 
response rate for placebo. Based on 
these ﬁ  ndings and no evidence of 
differences among these drugs in adult 
populations, the authors concluded 
that most newer antidepressants are 
likely effective, and that different 
results have been largely due to 
methodological differences in studies 
of CAD. They concluded, therefore, 
that at least ﬂ  uoxetine is clinically 
effective for CAD.
  Methodologic  Oversights 
in Published Studies
    The TADS concluded that “medical 
management of MDD with ﬂ  uoxetine, 
including careful monitoring for 
adverse events, should be made 
widely available” [23]. However, 
some researchers disagree with this 
conclusion [25].
    The TADS explores four 
experimental arms: placebo, 
ﬂ  uoxetine, CBT, and CBT + ﬂ  uoxetine. 
Some of these treatment groups were 
“blind” (i.e., participants were unaware 
of what treatment they were receiving, 
as in the case for placebo) while others 
were informed (as in the case for CBT). 
However, Table 2 shows the difﬁ  culty 
of interpreting a study that compares 
blinded and unblinded treatment 
groups (e.g., differences between 
treatment groups might be due to 
the varying inﬂ  uence of expectation). 
Thus, in the interpretation of the 
TADS ﬁ  ndings, subtle methodological 
caveats go unrecognized.
    Relative to other studies, CBT 
does not fare well compared to both 
placebo and ﬂ  uoxetine in the TADS. 
However, other studies comparing 
antidepressants and CBT showed 
that both were moderately effective 
in relieving depression in adults 
[56]. Adult neuroimaging ﬁ  ndings 
suggest that the two methods work 
by improving the functioning of 
different brain circuits: CBT operates 
on cortical areas related to attention 
and comprehension, including 
the anterior cingulate cortex, 
whereas antidepressants operate on 
subcortical areas. Applying the adult 
data to children, these exploratory 
imaging results may provide both 
a context for testing drugs against 
nonpharmacological therapy and a 
basis for considering how to treat or 
even prevent depression in those who 
are most susceptible [57].
    Despite being regarded as 
efﬁ  cacious in adults, meta-analysis of 
published RCTs indicates that 75% of 
antidepressant response in adults is 
duplicated by placebo [58]. This initial 
meta-analysis was amply critiqued by 
Klein for multiple limitations [59]. 
However, follow-up analyses using a 
different data set taken from the FDA, 
to which Klein’s objections do not apply, 
again reported that about 80% of the 
response to antidepressants in adults was 
duplicated in placebo control groups 
[60,61]. Together with the notion that 
antidepressant medication effects are 
typically weaker in children than adults 
[58,60], these conclusions accord with 
earlier reviews that challenge the effects 
of antidepressants in CAD [4,62–67]. 
Merely labeling a pill an antidepressant 
does not make it so. In fact, the existing 
data suggest that antidepressants are 
probably more effective in treating 
anxiety than depression [68].
    Another limitation draws on the 
implications of using antidepressants 
in early life [69]. Serotonin acts as 
a brain and glial growth factor in 
early development. Some serotonin 
receptors act during development 
to establish normal anxiety-like 
behavior later in life, while others 
play a role in synapse formation 
[70,71]. Some exploratory ﬁ  ndings 
suggest that artiﬁ  cial perturbation of 
serotonin function in early life may 
alter the normal development of 
brain systems related to stress, motor 
development, and motor control 
[71,72]. Furthermore, early exposure 
to ﬂ  uoxetine produced abnormal 
emotional behaviors in adult mice 
[69]. The critical role of serotonin in 
the maturation of brain systems that 
modulate emotional function in the 
adult suggests that, in concert with 
genetic makeup, low serotonin levels 
during early development may increase 
vulnerability to psychiatric disorders 
[69,73]. Early exposure to SSRIs, 
therefore, can potentially exact a heavy 
price in later life [74,75].
    These caveats suggest that, in 
addition to the potential implications 
of using antidepressants in early 
life, there are few compelling data 
sets, free of funding from drug 
companies, concerning the efﬁ  cacy of 
antidepressant medications over and 
above their placebo value for CAD. 
These caveats also show the difﬁ  culty 
of assessing the clinical signiﬁ  cance 
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  Table 2.   A Subtle Flaw in the TADS: Condition I versus Condition II   
Condition I Blind or Not Blind Condition II Blind or Not Blind
Placebo Blind Fluoxetine Blind
CBT Not blind Fluoxetine Blind
CBT and Fluoxetine Both not blind Fluoxetine Blind
CBT and Fluoxetine Both not blind Fluoxetine Not blind
    In the TADS [23], one of the better studies in the ﬁ  eld, half the participants knew what treatment they were getting. The TADS treatment comparisons report 
differences between placebo (blind) versus ﬂ  uoxetine (blind); CBT (not blind) versus ﬂ  uoxetine (blind); and CBT plus ﬂ  uoxetine (both not blind) versus 
ﬂ  uoxetine (blind). It is difﬁ  cult to interpret ﬁ  ndings comparing a blind arm of an experiment with one that is not blind. Given that it is difﬁ  cult to blind CBT [96], 
critical comparisons such as that of CBT plus ﬂ  uoxetine versus ﬂ  uoxetine (all not blind) were not included in the TADS study, although perhaps they should have 
been.
  DOI:  10.1371/journal.pmed.0030009.t002 PLoS Medicine  |  www.plosmedicine.org 0039
of the unique effects attributable to 
antidepressant medications. Because 
antidepressants work just slightly better 
than placebos, even according to 
data endorsed by the pharmaceutical 
industry, the image of antidepressants 
as more effective may be overreaching 
and perhaps a consequence of 
methodological artifacts [76].
    Public Health versus Individual 
Decisions
    The US Surgeon General makes 
decisions based on the greater good 
of a vast population: a mere two-
point improvement on the Hamilton 
depression scale may constitute a 
meaningful public-health beneﬁ  t (D. 
Shaffer, unpublished data). However, 
parents decide whether their depressed 
adolescent child should receive CBT, 
ﬂ  uoxetine, or start a vigorous exercise 
regime, based on an individually 
tailored risk-beneﬁ  t analysis.
    Most clinicians recommend 
psychotherapy for mild to moderate 
CAD and reserve SSRIs for severe 
CAD or when therapy is not effective 
[21]. Yet given the large numbers 
of people suffering from depressive 
disorders (i.e., an estimated 1.5 million 
adolescents (12–18 years of age) with 
MDD in the US alone [77]), it is easy 
to see why offering therapy would be 
difﬁ  cult (e.g., number of therapists 
and insurance considerations), thereby 
making the drug option more popular.
    Despite early suggestions in the 
literature [78–80], accounts of the 
association between adult suicidality 
and the use of SSRIs have been 
inconclusive [81–83]. One early 
meta-analysis showed that SSRIs 
potentially decreased suicidal ideation 
as measured by a single question on 
the Hamilton depression score [83], 
but a more recent study reported a 
non-signiﬁ  cant increase in suicide 
rates between patients assigned to 
SSRIs and those assigned to placebo or 
other antidepressants [82]. Despite the 
FDA’s black-box label, some accounts 
suggest that since the introduction 
of SSRIs the number of successful 
suicides has steadily declined [84,85]. 
One recent meta-analysis reported 
that SSRIs increased the risk of suicide 
attempts, but not completions, across 
all indications [86]. Another, a meta-
analysis of drug company data that were 
submitted to the MHRA’s safety review, 
reported that SSRIs did not appear to 
increase the risk of suicide attempts or 
thoughts [87]. 
    Data regarding SSRIs and youth 
suicide are sparser, but no less 
controversial [12,13,88,89]. One 
study reported an inverse relationship 
between regional change in use of 
antidepressants and suicide [90]. 
Nonetheless, the highest possible 
standard should be applied to scientiﬁ  c 
data involving drug treatment of 
children because they are essentially 
involuntary patients: when a 
medication is prescribed for a young 
child, the adult caregiver ensures 
that the child takes the medication, 
regardless of the child’s own desires. 
Yet, studies of adolescent compliance 
with medication treatment report 
notoriously low compliance outside of 
the controlled settings of clinical trials.
    The sparse RCT ﬁ  ndings suggest 
that improvement may not always be 
clinically signiﬁ  cant. When evaluating a 
medication with side effects, potential 
clinical implications for later life, and 
questionable effectiveness, it should 
be compared to interventions such as 
exercise and CBT, which have shown 
some therapeutic effects on depression 
without medical side effects and risks 
[91]. Originally celebrated but recently 
disparaged by modern psychiatry, 
therapeutic rapport may prove 
more clinically signiﬁ  cant than drug 
speciﬁ  city.
  Conclusions
    Given all of these limitations, patients 
and physicians should demand 
stronger evidence for the efﬁ  cacy of 
antidepressants for CAD.
    Some advocates assert that rather 
than using medication with side effects 
and low effectiveness, children should 
be offered interventions that produce 
therapeutic effects on depression 
without the medical side effects 
and associated risks [91]. However, 
clinicians and laypeople must apply 
comparable standards for evaluating 
the efﬁ  cacy of drug and psychotherapy 
data. Whereas medical drug research 
occurs in a formally regulated, albeit 
imperfect, environment, safety and 
efﬁ  cacy in psychotherapy research are 
largely unregulated. Moreover, unlike 
drug assays, psychotherapy studies do 
not typically report adverse events, 
their meta-analyses are sparse, and their 
experimental design lacks a placebo 
condition (see Table 2).
    Finally, although antidepressants 
undoubtedly affect brain biochemistry, 
interpreting these neural changes is 
controversial, and a risk-beneﬁ  t analysis 
of side effects and long-term health 
risks may cast a long shadow on the 
current preference for antidepressants 
as ﬁ  rst-line treatment for CAD. Only 
more studies, and the passage of 
enough time to examine the putative 
long-term effects, will determine the 
efﬁ  cacy of antidepressants in CAD. 
Clinicians, patients, families, and the 
public should be cognizant of these 
issues and exercise critical judgment as 
they make informed decisions.   
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Patients and physicians 
should demand stronger 
evidence for the efﬁ  cacy 
of antidepressants.
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